Key points are not available for this paper at this time.
Design
Editorial
Discusses the implications of the LIFE trial and anticipates answers from the upcoming VALUE trial regarding the efficacy of ARBs in hypertension.
The results of the LIFE (Losartan Intervention for Endpoint Reduction) trial were the first demonstration that there are differences in outcomes between antihypertensive medications, beyond the reduction in blood pressure. For the first time, a ‘new’ antihypertensive medication, an angiotensin-receptor blocker (ARB) was shown to be superior over an ‘old’ drug, a beta blocker. However, there are questions remaining after LIFE, such as: was the reduction in stroke specific to ARBs? Why were there no greater reductions in cardiovascular mortality? What is the role of monotherapy versus a combination of ARB and a diuretic? Answers to several of these and other questions are expected from the VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial.
No takes yet. Share an insight, caveat, or question.
Stevo Julius (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: